Advances in Inflammatory Bowel Diseases (AIBD) 2024 Annual Conference

Orlando, Florida, US 09 December 2024 - 11 December 2024

SC infliximab biosimilar boosts healing along all bowel segments under colonoscopy in CD

05 Feb 2025 by

The efficacy of maintenance with a modified biosimilar of infliximab in promoting healing of inflamed mucosa in CD is observed across all SES-CD segments, a post hoc analysis of the LIBERTY-CD trial has shown

SC infliximab biosimilar boosts healing along all bowel segments under colonoscopy in CD

05 Feb 2025

One monoclonal antibody outdoes another in real-world ulcerative colitis study

22 Jan 2025 by

The integrin receptor antagonist vedolizumab mostly works as well as the TNF-alpha inhibitor infliximab in biologic-naïve patients with moderate-to-severe ulcerative colitis treated in the real-world setting, although vedolizumab slightly surpasses infliximab in terms of inducing endoscopic response and remission while having a better safety profile, according to a study.

One monoclonal antibody outdoes another in real-world ulcerative colitis study

22 Jan 2025

No increase in CV risk with JAKi vs TNFi for IBD

21 Jan 2025 by

Among patients with inflammatory bowel disease (IBD), treatment with Janus kinase inhibitors (JAKi) does not increase the risk of major adverse cardiovascular events (MACE) compared with tumour necrosis factor inhibitors (TNFi), according to a study presented at AIBD 2024.

No increase in CV risk with JAKi vs TNFi for IBD

21 Jan 2025

Novel drug for moderate-to-severe UC yields quality-of-life benefits

20 Jan 2025 by

RO7790121, an antibody against tumour necrosis factor-like ligand 1A (Anti-TL1A), helps improve the health-related quality of life (HR-QoL) for patients with moderately to severely active ulcerative colitis (UC), as shown in the phase IIb TUSCANY-2 trial.

Novel drug for moderate-to-severe UC yields quality-of-life benefits

20 Jan 2025

IBD linked to increased risk of hidradenitis suppurativa

18 Jan 2025 by

Inflammatory bowel disease (IBD) is associated with an increased risk of hidradenitis suppurativa (HS), according to a study presented at AIBD 2024.

IBD linked to increased risk of hidradenitis suppurativa

18 Jan 2025

Quality of life gains seen with mirikizumab regardless of prior biologic failure for CD

17 Jan 2025 by

Mirikizumab helps improve health-related quality of life (HRQoL) in Crohn’s disease (CD) patients, including those who have not had success with a biologic therapy, according to data from the phase III VIVID-1 study.

Quality of life gains seen with mirikizumab regardless of prior biologic failure for CD

17 Jan 2025

Does hormone therapy affect IBD outcomes in transgender, nonbinary patients?

15 Jan 2025 by

Disease activity, as measured by C-reactive protein (CRP), foecal calprotectin (FC), and endoscopic evaluation, does not significantly vary a year following the initiation of gender-affirming hormone (GAH) therapy in transgender and gender nonconforming patients with inflammatory bowel disease (IBD), as shown in a study presented at AIBD 2024.

Does hormone therapy affect IBD outcomes in transgender, nonbinary patients?

15 Jan 2025

Ozanimod delivers real-world clinical benefits in ulcerative colitis

14 Jan 2025 by

Treatment with ozanimod (oza) attains high efficacy rates in real-world clinical practice at week 12 for advanced therapy (AT)-naive patients with moderate-to-severe ulcerative colitis (UC) and at week 26 for those with AT exposure, as shown by initial results from POLARIS, an ongoing phase IV open-label study.